[8]
On the 25th of June, 1997, Novopharm served a Notice of Allegation on Merck, pursuant to the
Regulations
, in respect of its application for an NOC for enalapril maleate alleging that no claim to the medicine itself and no claim for the use of the medicine would be infringed by its making, constructing, using or selling of the drug for which the submission for the NOC had been filed because:
"All of the bulk raw material which Novopharm will be using to manufacture the finished Drug for sale in Canada was purchased prior to the date of issuance of the earliest of the Patents. Specifically, all of Novopharm's raw material was purchased prior to October 16, 1990, the date of issuance of Canadian Patent 1,275,349 ..."